‘‘Karuna plans an NDA submission to the FDA later this year that incorporates the efficacy and safety data from all three short-term EMERGENT trials plus the additional long-term safety data from upcoming studies. The company hopes the drug is approved by the second half of 2024.’’
7 Likes
I think that if they want the drug to be approved for the second half of 2024. That means that we will have the drug on the market at the beginning of 2025.
A year and a half to go, let’s not lose hope, time goes by fast.
2 Likes
time goes by fast
Is fact, let’s ride this out. And maybe we’ll have something really good that gives us much needed luck!
2 Likes
While traditional antipsychotic medications primarily target dopamine receptors in the brain, KarXT preferentially activates the M1 and M4 neuroreceptors.
This sounds like good news. I need more M1 receptor binding to the hippocampus. This should increase memory and learning. Hypothetically.
KarXT combines an anticholinergic. Would this override the need for anticholinergic PRN?
2 Likes